Salute e Benessere

Darolutamide receives EU approval in third indication for patients with advanced…

ORION CORPORATIONPRESS RELEASE21 JULY 2025 at 10:30 EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancerEuropean Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Approval is based on positive results from the pivotal Phase III ARANOTE trial.This broadened indication allows doctors to use...
Nasdaq GlobeNewswire
21/07/2025

EssilorLuxottica to acquire PUcore’s division dedicated to the development…

EssilorLuxottica to acquire PUcore’s division dedicated to the development, manufacturing and sale of ophthalmic lens materials The acquisition will enhance the Group’s R&D and production capabilities for the manufacturing of innovative high index, thinner and lighter ophthalmic lenses, and ensure long term sustainable sourcingParis, France (21 July 2025)– EssilorLuxottica announces today it has signed an agreement with the South Korean company PUcore for the acquisition of all...
Nasdaq GlobeNewswire
21/07/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on…

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksThe phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeksThe safety profile of astegolimab was consistent with previously reported data, with no new safety signals identifiedAnalysis of the ALIENTO and ARNASA data...
Nasdaq GlobeNewswire
21/07/2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.Copenhagen, Denmark, July 18, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:As of 17 July 2025, Van...
Nasdaq GlobeNewswire
18/07/2025

Disclosure of notification received from Alychlo

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET Disclosure of notification received from AlychloFagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV. Notification by Alychlo NVOn 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the...
Nasdaq GlobeNewswire
18/07/2025

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for…

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – ®(mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above. EZMEKLY is the first and only therapy approved in the European Union (EU) for both adults and children with NF1-PN...
Nasdaq GlobeNewswire
18/07/2025

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR…

To explore the valuable insights in the Preservative Free Eye Drops Market report, you can easily download a sample PDF of the report – https://www.theinsightpartners.com/sample/TIPRE00038962 To explore the valuable insights in the Preservative Free Eye Drops Market report, you can easily download a sample PDF of the report –https://www.theinsightpartners.com/sample/TIPRE00038962 The preservative-free eye drops market is segmented on the basis of type, application, and distribution...
PR Newswire
18/07/2025

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR |…

Browse in-depth TOC on 'Sleep Apnea Devices Market' Browse in-depth TOC on 'Sleep Apnea Devices Market' 739 - Tables 51 - Figures 497 - Pages By product type,the sleep apnea devices market is categorized into two main product types: therapeutic devices and diagnostic devices. In 2024, the therapeutic devices segment emerged as the dominant player in the market, capturing the largest share. This growth can be attributed to continuous advancements in technology focused on...
PR Newswire
18/07/2025

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR…

To explore the valuable insights in the Technetium-99m Market report, you can easily download a sample PDF of the report- https://www.theinsightpartners.com/sample/TIPRE00029981 Some of the reasons behind Tc-99m's medical popularity are its ideal imaging properties, such as a short half-life of about six hours, suitable gamma energy, as well as providing a low radiation dose, giving it the capability to image organs such as the brain, heart, bones, lungs, kidneys, thyroid,...
PR Newswire
18/07/2025

Healthcare Dispensing Systems Market worth $6.27 billion by 2030 with 6.3% CAGR…

Browse in-depth TOC on "Healthcare Dispensing Systems Market" Browse in-depth TOC on "Healthcare Dispensing Systems Market" 400 - Tables 50 - Figures 400 - Pages By type,the market is divided into automatic dispensing systems, semi-automated dispensing systems, stand-alone/manual dispensing instruments, and OEM/dispensing components. Automatic dispensing systems accounted for the largest share of the healthcare dispensing systems market in 2024. Their dominance is...
PR Newswire
18/07/2025

Orion Group Half-Year Financial Report January–June 2025

ORION CORPORATIONHALF-YEAR FINANCIAL REPORT 1–6/202518 JULY 2025 at 12:00 EESTOrion Group Half-Year Financial Report January–June 2025April–June 2025 HighlightsNet sales totalled EUR 416.5 (April–June 2024: 328.2) million Operating profit was EUR 104.6 (65.8) millionBasic earnings per share were EUR 0.59 (0.37)Cash flow from operating activities per share was EUR 0.57 (0.20)Outlook for 2025 was upgraded in July: Net sales are estimated to be EUR 1,630 million to EUR...
Nasdaq GlobeNewswire
18/07/2025

EQT to acquire Adalvo, a leading B2B dossier developer

EQT will invest in the next phase of Adalvo's growth journey through targeted investments in R&D, supply chain, and operational excellence. This will help expand its product portfolio with a steady cadence of new launches, expand the robust supply chain to cover a wide range of partners and jurisdictions, and enhance business development opportunities for its partners through greater flexibility, reach, and speed to market. EQT will invest in the next phase of Adalvo's growth journey…
PR Newswire
18/07/2025

Orion Corporation’s financial reporting and Annual General Meeting in 2026

ORION CORPORATIONSTOCK EXCHANGE RELEASE – FINANCIAL CALENDAR18 JULY 2025 at 9.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2026 Orion Corporation will publish its Financial Statement Release 2025 on Thursday, 12 February 2026.The publication dates of the Interim Reports and the Half-Year Financial Report in 2026 are as follows: Interim Report January-March 2026Thursday 23 April 2026Half-Year Financial Report January-June 2026...
Nasdaq GlobeNewswire
18/07/2025

Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief…

Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development Atif Abbas, MD joins as CMO, bringing over 25 years’ experience in oncology drug development and clinical and regulatory strategyCarolyn Edwards, PhD appointed VP, R&D, with over 15 years’ expertise in drug development and strategic partneringEdinburgh, UK, 18 July 2025 - Trogenix Ltd (“Trogenix”), a...
Nasdaq GlobeNewswire
18/07/2025

The World Federation of Neurology to Host Global Webinar Uniting UN-ECOSOC, WHO…

"When one in three is affected by a brain disorder—and nearly 90% of this burden occurs in low- and middle-income countries, this campaign becomes not just important, but essential," said Professor Tissa Wijeratne, Co-Chair of World Brain Day. "It reflects a global commitment to protecting brain health across one's entire lifespan, from preconception through aging adulthood, ensuring that no one is left behind." "When one in three is affected by a brain disorder—and…
PR Newswire
18/07/2025

Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint MedicinesParis, July 18, 2025. Sanofi today announces the completion of itsacquisition of Blueprint Medicines Corporation(Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists,...
Nasdaq GlobeNewswire
18/07/2025

SERM Market Shows Promising Growth Trajectory During the Study Period…

Key Takeaways from the SERM Market Report Key Takeaways from the SERM Market Report Discover which indication is expected to grab the major SERM market share @SERM Market Report SERM Market Dynamics The SERM market is witnessing dynamic growth, driven by anincreasing prevalence of hormone-related disorderssuch as breast cancer, osteoporosis, and infertility. SERMs function by selectively stimulating or inhibiting estrogen receptors in different tissues, offering...
PR Newswire
17/07/2025

Facioscapulohumeral Muscular Dystrophy Market Gearing Up for Outstanding…

Roughly 80% of individuals carrying the FSHD gene mutation experience symptoms, while the remaining 20% are asymptomatic, either showing no signs or only very mild symptoms that may go unnoticed until later in life. For FSHD1, children of an affected parent have a 50% likelihood of inheriting the disorder. In FSHD2, the inheritance risk depends on the genetic background of both parents, typically ranging from 25% to 50%. Roughly80%of individuals carrying the FSHD gene mutation experience...
PR Newswire
17/07/2025

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels

OSE Immunotherapeutics Launches Newsletter for Individual ShareholdersNANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally...
Nasdaq GlobeNewswire
17/07/2025

EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call…

Second-Quarter and First-Half 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Second-Quarter and First-Half 2025 Results Conference Call on: Monday, July 28, 2025, at 6:30 pm CEST Dial-in telephone access:If you wish to dial into the...
Nasdaq GlobeNewswire
17/07/2025

Patient-Derived Xenograft Model Market Size at USD 1.12 Billion in 2031…

The report analyzes market trends, key players, and future opportunities in-depth. The patient-derived xenograft model market comprises a vast array of products and services expected to register strength in the coming years. The report analyzes market trends, key players, and future opportunities in-depth. The patient-derived xenograft model market comprises a vast array of products and services expected to register strength in the coming years. To explore the valuable insights in the...
PR Newswire
17/07/2025

ECG Sensor Patches Market worth $2.32 billion by 2032 with 12.0% CAGR |…

Browse in-depth TOC on "ECG Sensor Patches Market" Browse in-depth TOC on "ECG Sensor Patches Market" 270 - Tables 57 - Figures270 - Pages By lead type,the single-lead ECG Sensor Patch segment accounted for the largest market share in 2024 due to its high clinical utility in ambulatory cardiac rhythm tracking, particularly for arrhythmia and post-operative monitoring. These patches are favored in outpatient and home settings because they are lightweight, unobtrusive, and...
PR Newswire
17/07/2025

Pharmaceutical Packaging Equipment Market worth $14.3 billion by 2030 with 6.3%…

Browse in-depth TOC on "Pharmaceutical Packaging Equipment Market" Browse in-depth TOC on "Pharmaceutical Packaging Equipment Market" 361 - Tables 57 - Figures 404 - Pages By product,Primary packaging equipment plays a crucial role in the pharmaceutical industry, holding the largest market share due to its direct impact on safeguarding the integrity, sterility, and efficacy of various drug formulations. This equipment is essential for an array of dosage forms, including...
PR Newswire
17/07/2025

UroMems Receives Clearance from the FDA and the French ANSM for Initiating…

This prospective, multicenter trial, called the SOPHIA2 study, will evaluate the safety and efficacy of the UroActive System, the first smart automated artificial urinary sphincter (AUS) for the treatment of SUI. The FDA IDE approval and ANSM clearance follow strong feasibility study results for both women and men in France. This prospective, multicenter trial, called the SOPHIA2 study, will evaluate the safety and efficacy of the UroActive System, the first smart automated artificial urinary...
PR Newswire
17/07/2025
Altri  Comunicati